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Objectives: We sought to elucidate the effects of vasopressin on modulating the endotoxin-induced
upregulation of inﬂammatory mediators.
Materials and Methods: A conﬂuent murine macrophage-like cell line, RAW264.7 cells, were treated with
lipopolysaccharide (LPS) (100 ng/mL) or with LPS plus vasopressin (10 pg/mL, 100 pg/mL, or 1000 pg/
mL); the cells were denoted as the LPS group, the LPS-V(10) group, the LPS-V(100) group, and the LPS-
V(1000) group, respectively. The respective control groups were run simultaneously. Vasopressin was
administered immediately after LPS. The expression of inﬂammatory molecules was then assayed. The
molecules that were assayed included the chemokine macrophage-inﬂammatory protein-2 (MIP-2); the
cytokines tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b), and interleukin-6 (IL-6); nitric oxide
(NO)/inducible NO synthase (iNOS); and prostaglandin E2 (PGE2)/cyclooxygenase-2 (COX-2).
Results: The differences between the LPS and LPS-V(10) groups in the concentration of inﬂammatory
mediators were not statistically signiﬁcant. By contrast, the LPS-V(100) and LPS-V(1000) groups were
signiﬁcantly lower than the LPS group in the concentration of MIP-2 (p ¼ 0.004 and p ¼ 0.001,
respectively), TNF-a (p ¼ 0.045 and p ¼ 0.007, respectively), IL-1b (p ¼ 0.003 and p < 0.001, respectively),
NO (p ¼ 0.014 and p ¼ 0.001, respectively), iNOS mRNA (p ¼ 0.001 and p < 0.001, respectively), PGE2
(p ¼ 0.021 and p < 0.001, respectively), and COX-2 mRNA (p ¼ 0.021 and p ¼ 0.006, respectively). The IL-6
concentration was moreover signiﬁcantly lower in the LPS-V(1000) group than in the LPS group
(p < 0.001), whereas the IL-6 concentration in the LPS-V(100) and the LPS groups was not signiﬁcantly
different.
Conclusion: In a dose-dependent manner, vasopressin inhibited the endotoxin-induced upregulation of
inﬂammatory mediators in activated murine macrophages.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
It is well-established that the endotoxin-induced upregulation
of inﬂammatory mediators such as the chemokines [e.g.,
macrophage-inﬂammatory protein-2 (MIP-2)]; the cytokines [e.g.,
tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b), and
interleukin-6 (IL-6)]; nitric oxide (NO)/inducible NO synthase
(iNOS); and prostaglandin E2 (PGE2)/cyclooxygenase-2 (COX-2) are
crucial in mediating the systemic inﬂammatory response during
sepsis [1e4]. In this response, septic patients have inappropriateogy, Buddhist Tzu Chi General
trict, New Taipei City, Taiwan.
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ddhist Compassion Relief Tzu Chivasodilatation and myocardial dysfunction that can result in
hypoperfusion and eventually dysfunction of vital organs [5]. Pre-
vious data further indicate that modulating the systemic inﬂam-
matory response through inhibiting the endotoxin-induced
upregulation of inﬂammatory mediators could reduce the patho-
logical sequelae of sepsis, and thereby be a beneﬁcial therapeutic
strategy against sepsis [6,7].
Vasopressin is an endogenous nonapeptide synthesized in the
paraventricular nuclei within the hypothalamus [8,9]. Vasocon-
striction and antidiuresis are two well-known physiological func-
tions of vasopressin [8,9]. Clinical observations reveal that septic
patients tend to have low circulating concentrations of endogenous
vasopressin [10e12]. A signiﬁcant increase in sensitivity to exoge-
nous vasopressin during sepsis has also been reported [13,14].
Previous data further reveal that exogenous vasopressin can restore
aortic blood ﬂow and preserve perfusion to vital organs [15,16].Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
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vasopressin in the management of sepsis [17].
Previous data also have revealed that exogenous vasopressin
decreases pulmonary inﬂammation in a rodent model of sepsis
[18]. These data seem to indicate that the mechanisms underlying
the observed beneﬁcial effects of exogenous vasopressin during
sepsis and vasopressin’s effect on restoring organ perfusion may
involve modulating the inﬂammatory response. To date, direct
evidence depicting the effects of vasopressin in this regard are
lacking. For further elucidation, we conducted this study with the
hypothesis that vasopressin could inhibit the endotoxin-induced
upregulation of inﬂammatory mediators in activated macrophages.
2. Materials and methods
2.1. Cell culture and cell activation protocols
To facilitate our investigation, we employed RAW264.7 cells,
which are an immortalized murine macrophage-like cell line that
can readily express inﬂammatory mediators on exposure to endo-
toxin [19]. The RAW264.7 cells were grown in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Life Technologies, Grand Island, NY, USA)
and incubated in a humidiﬁed chamber at 37C in a mixture of 95%
air and 5% CO2. Prior to the experiments, the cells were plated on 6-
well dishes (1e2 106 cells per well; Corning, Acton, MA, USA). The
culture medium was changed every day for a routine culture, and
then changed 1 hour prior to each experiment. Cells under passage
20 were used for experiments. After reaching 80% conﬂuency, the
RAW264.7 cells were activated with Gram-negative endotoxins
[lipopolysaccharide (LPS, 100 ng/mL) and Escherichia coli serotype
0127:B8 endotoxin; Sigma-Aldrich, St. Louis, MO, USA] to induce
the upregulation of inﬂammatory mediators, as we have previously
reported [20].
2.2. Experimental protocols
The RAW264.7 cells were randomized to receive phosphate-
buffered saline (PBS) (Life Technologies); vasopressin (V; 1000 pg/
mL; Life Technologies); LPS; or LPS plus vasopressin (10 pg/mL,
100 pg/mL, or 1000 pg/mL). The cells were designated as the PBS
group, the V(1000) group, the LPS group, the LPS-V(10) group, the
LPS-V(100) group, and the LPS-V(1000) group, respectively. Each
group contained six culture dishes (n ¼ 6). Vasopressin was
administered immediately after LPS. After reacting with LPS for 24
hours (or for a comparable duration in groups without LPS), the cell
cultures from each group were harvested. The vasopressin dosage
range (10e1000 pg/mL) was determined on the basis of the plasma
concentrations of patients receiving exogenous vasopressin for the
treatment of sepsis [10].
2.3. Inﬂammatory mediator measurements
Freshly harvested culture media were analyzed by the respec-
tive enzyme-linked immunosorbent assay (ELISA) kits (R&D Sys-
tems, Minneapolis, MN, USA) for the concentrations of MIP-2, the
cytokines (i.e., TNF-a, IL-1b, and IL-6), and PGE2. Freshly harvested
culture media were also analyzed for the concentrations of stable
NOmetabolites, nitrite, and nitrate by using a colorimetric assay kit
(Cayman Chemical, Ann Arbor, MI, USA).
2.4. Analyses of iNOS and COX-2 transcriptional expression
The transcriptional expressions of iNOS and COX-2 were
analyzed by reverse transcription and polymerase chain reaction(RT-PCR) [21,22]. The primer sequences and ampliﬁcation protocols
for iNOS, COX-2, and b-actin (as the internal standard) were
adopted, based on previous reports [21,22]. RNA isolation, mRNA
conversion to complementary DNA (cDNA) using reverse tran-
scription (RT), and polymerase chain reaction (PCR) ampliﬁcation
were performed in accordance with previous protocols [21,22].
After separation, the PCR-ampliﬁed cDNA band densities were
quantiﬁed by using densitometric techniques (Scion Image for
Windows; Scion Corp., Frederick, MD, USA).
2.5. Statistical analysis
Data were analyzed by using one-way analysis of variance with
the Tukey post hoc test to determine the between-group differ-
ences. Data are presented as the mean  standard deviation. The
signiﬁcance level was set at 0.05. A commercial software package
(SigmaStat for Windows; SPSS Science, Chicago, IL, USA) was used
for data analysis.
3. Results
3.1. Chemokines and cytokines
Fig. 1 illustrates the chemokine and cytokine data. The con-
centrations of MIP-2, TNF-a, IL-1b, and IL-6 in the PBS and V(1000)
groups were low. As we expected, the concentrations of MIP-2,
TNF-a, IL-1b, and IL-6 were signiﬁcantly higher in the LPS group
than in the PBS group (p < 0.001 for all substances). The difference
between the LPS-V(10) and LPS groups was not signiﬁcant in the
concentrations of MIP-2, TNF-a, IL-1b, and IL-6. However, the LPS-
V(100) and LPS-V(1000) groups were signiﬁcantly lower than the
LPS group in the concentrations of MIP-2 (p ¼ 0.004 and p ¼ 0.001,
respectively), TNF-a (p ¼ 0.045 and p ¼ 0.007, respectively), and IL-
1b (p ¼ 0.003 and p < 0.001, respectively). The IL-6 concentration
was signiﬁcantly lower in the LPS-V(1000) group than in the LPS
group (p < 0.001), whereas the IL-6 concentration was not signif-
icantly different between the LPS-V(100) and LPS groups.
Our data also revealed that the MIP-2 concentration was not
signiﬁcantly different between the LPS-V(10), LPS-V(100), and LPS-
V(1000) groups. The differences in the TNF-a and IL-6 concentra-
tions were not signiﬁcantly different between the LPS-V(10) and
LPS-V(100) groups. However, the IL-1b concentration was signiﬁ-
cantly lower in the LPS-V(100) group than in the LPS-V(10) group
(p ¼ 0.029). The TNF-a, IL-1b, and IL-6 concentrations were
moreover signiﬁcantly lower in the LPS-V(1000) group than in the
LPS-V(10) group (p ¼ 0.028, p < 0.001, and p < 0.001, respectively).
The IL-6 concentration was signiﬁcantly lower in the LPS-V(1000)
group than in the LPS-V(100) group (p ¼ 0.019), whereas the
TNF-a and IL-1b concentrations were not signiﬁcantly different
between the LPS-V(1000) and LPS-V(100) groups.
3.2. NO, iNOS mRNA, PGE2, and COX-2 mRNA
Fig. 2 illustrates the data on NO, iNOS mRNA, PGE2, and COX-2
mRNA. The concentrations of NO, iNOS, PGE2, and COX-2 were
signiﬁcantly higher in the LPS group than in the PBS group
(p < 0.001 for all substances). The differences in the concentrations
of NO, iNOS, PGE2, and COX-2 similarly were not signiﬁcantly
different between the LPS-V(10) and LPS groups. By contrast, the
LPS-V(100) and LPS-V(1000) groups were signiﬁcantly lower than
the LPS group in the concentrations of NO (p ¼ 0.014 and p ¼ 0.001,
respectively); iNOS (p ¼ 0.001 and p < 0.001, respectively); PGE2
(p ¼ 0.021 and p < 0.001, respectively); and COX-2 (p ¼ 0.020 and
p ¼ 0.006, respectively). The differences in the concentrations of
NO, iNOS, PGE2, and COX-2 moreover were not signiﬁcantly
Fig. 1. The concentrations of (A) macrophage inﬂammatory protein-2 (MIP-2), (B) tumor necrosis factor-a (TNF-a), (C) interleukin (IL)-1b, and (D) IL-6 in murine macrophage
RAW264.7 cells. The data are derived from 6 culture dishes from each group and expressed as the mean  standard error. LPS ¼ the lipopolysaccharide (100 ng/mL) group; LPS-V
(10) ¼ the LPS plus vasopressin (10 pg/mL) group; LPS-V(100) ¼ the LPS plus vasopressin (100 pg/mL) group; LPS-V(1000) ¼ the LPS plus vasopressin (1000 pg/mL) group; PBS ¼ the
phosphate-buffered saline group; V(1000) ¼ the vasopressin (1000 pg/mL) group. * p < 0.05, vs. the PBS group. # p < 0.05, vs. the LPS group. y p < 0.05, the LPS-V(100) or LPS-
V(1000) group vs. the LPS-V(10) group. z p < 0.05 the LPS-V(1000) group vs. the LPS-V(100) group.
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centrations of NO and COX-2 in the LPS-V(1000) and LPS-V(10)
groups were not signiﬁcantly different. However, the concentra-
tions of iNOS and PGE2 were signiﬁcantly lower in the LPS-V(1000)Fig. 2. The concentrations of (A) nitric oxide (NO) and (B) prostaglandin E2 (PGE2), and repr
and cycloosygenase-2 (COX-2) mRNA in murine macrophage RAW264.7 cells. The expressi
merase chain reaction (RT-PCR). The data are derived from six culture dishes from each grou
mL) group; LPS-V (10) ¼ the LPS plus vasopressin (10 pg/mL) group; LPS-V(100) ¼ the LPS p
mL) group; PBS ¼ the phosphate-buffered saline group; V(1000) ¼ the vasopressin (1000 pg
V(100) or LPS-V(1000) group vs. the LPS-V(10) group. zp < 0.05 the LPS-V(1000) group vs.group than in the LPS-V(10) group (p < 0.001 and p ¼ 0.045,
respectively). The iNOS concentrationwas signiﬁcantly lower in the
LPS-V(1000) group than in the LPS-V(100) group (p ¼ 0.009). By
contrast, the concentrations of NO, PGE2, and COX-2 were notesentative gel photography and densitometric analysis of inducible NO synthase (iNOS)
on of iNOS and COX-2 mRNA were analyzed by using reverse transcription and poly-
p and expressed as mean  standard deviation. LPS ¼ the lipopolysaccharide (100 ng/
lus vasopressin (100 pg/mL) group; LPS-V(1000) ¼ the LPS plus vasopressin (1000 pg/
/mL) group. *p < 0.05, vs. the PBS group. #p < 0.05, vs. the LPS group. yp < 0.05, the LPS-
the LPS-V(100) group.
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4. Discussion
Data from the current study, in concert with data from previous
studies [1e4], conﬁrmed that endotoxins can induce signiﬁcant
upregulation of inﬂammatorymediators. Our data revealed that the
concentrations of chemokines, cytokines (e.g., TNF-a, IL-1b, and IL-
6), NO/iNOS mRNA, and PGE2/COX-2 mRNA were signiﬁcantly
higher in murine macrophages that were treated with endotoxin
than in macrophages treated with PBS. Data from this study also
demonstrated that vasopressin at a dosage of 10 pg/mL posed no
signiﬁcant effect on modulating the endotoxin-induced upregula-
tion of inﬂammatory mediators: our data revealed that the con-
centrations of inﬂammatory mediators in macrophages treated
with endotoxin plus 10 pg/mL of vasopressin and the concentra-
tions of inﬂammatory mediators in macrophages treated with
endotoxin alone were comparable. By contrast, our data demon-
strated that vasopressin at dosages of 100 pg/mL and 1000 pg/mL
could signiﬁcantly inhibit the endotoxin-induced upregulation of
inﬂammatory mediators: the concentrations of inﬂammatory me-
diators were signiﬁcantly lower in macrophages treated with
endotoxin plus 100 pg/mL or endotoxin plus 1000 pg/mL of vaso-
pressin than in macrophages treated with endotoxin alone. These
data conﬁrmed our hypothesis, and provide direct evidence that
vasopressin in a dose-dependent manner can inhibit the
endotoxin-induced upregulation of inﬂammatory mediators in
activated murine macrophages.
Our data conﬁrmed the potent anti-inﬂammatory effects of vaso-
pressin. However, the underlying mechanisms remain unstudied.
The expression of inﬂammatory mediators is tightly regulated
by the upstream transcriptional factors nuclear factor-kB (NF-kB)
and mitogen-activated protein kinases (MAPKs) [23,24]. The
cellular recognition of endotoxindincluding the binding of endo-
toxin to inﬂammatory cells and subsequent toll-like receptor 4
(TLR-4) activationdis essential in mediating the endotoxin-
induced activation of NF-kB and MAPKs [25e27]. Judging from
the crucial roles of the aforementioned signaling pathways in
regulating the expression of inﬂammatory mediators, we speculate
that vasopressin may act through inhibiting endotoxin binding and
thereby inhibiting the subsequent activation of TLR-4, NF-kB, and/
or MAPKs. In this way, vasopressin inhibits the endotoxin-induced
upregulation of inﬂammatory mediators. Previous data that NF-kB
activation in septic mice can be mitigated by vasopressin [28]
seems to support our speculation. More studies are needed
before further conclusions can be reached.
As mentioned previously, vasopressin has several important
physiological functions, including vasoconstriction and anti-
diuresis [8,9]. To exert vasoconstriction, vasopressin needs to
interact with V1 receptors located on vascular smooth muscle cells
[29]. To exert its antidiuretic effect, vasopressin needs to interact
with the V2 receptors located on the cells of the distal convoluted
tubules and collecting ducts [29]. Previous data nevertheless has
indicated that sepsis can downregulate the V1 receptors [30].
Previous data also reveals that the effects of vasopressin on miti-
gating sepsis-induced pulmonary inﬂammation could be blocked
by antagonizing the V2 receptors [18]. These data indicate the
involvement of the V1 and V2 receptors in sepsis. Judging from
these data, we further speculate that the anti-inﬂammatory effects
of vasopressin observed in this study may very likely involve the
V1 and/or V2 receptors.
In summary, our data conﬁrmed that vasopressin in a dose-
dependent manner inhibits the endotoxin-induced upregulation
of inﬂammatory mediators in activated murine macrophages.Acknowledgments
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